FLNA:BMV
Filana Therapeutics Inc
MXNÂ 15,92
0,00%
(0,00) 1D
5 Okt., 12:05:31 GMT-6 · MXN
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FLNA...
Mkt. cap
35,50Â m
Avg. vol.
0,00
Volume
0,00
52-wk high
MXNÂ 56,00
52-wk low
MXNÂ 15,92
No. of employees
19
Mkt. cap
35,50Â m
Avg. vol.
0,00
Volume
0,00
52-wk high
MXNÂ 56,00
52-wk low
MXNÂ 15,92
No. of employees
19
News stories
From web sources and news partners
www.dars.gov.et
·
2 weke gelede
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss of $0.22 Per Share Beats Estimates, Shares Rise 8.92%
Profile
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
About Filana Therapeutics Inc
CEO-
Employees19
Founded1998
HeadquartersAustin, Texas, Verenigde State van Amerika
SectorPharmaceutical industry
Websitepaintrials.com